Background: Hepatocellular Carcinoma (HCC) is a prevalent cancer in the world. As yet, there is no medication for complete treatment of HCC.

Objective: There is a critical need to search for an innovative therapy for HCC. Recently, multiepitope vaccines have been introduced as effective immunotherapy approach against HCC.

Methods: In this research, several immunoinformatics methods were applied to create an original multi-epitope vaccine against HCC consisting of CD8+ cytolytic T lymphocytes (CTLs) epitopes selected from α- fetoprotein (AFP), glypican-3 (GPC3), aspartyl-β-hydroxylase (ASPH); CD4+ helper T lymphocytes (HTLs) epitopes from tetanus toxin fragment C (TTFC), and finally, two tandem repeats of HSP70407-426 were used which stimulated strong innate and adaptive immune responses. All the mentioned parts were connected together by relevant linkers.

Results and Discussions: According to physicochemical, structural, and immunological results, the designed vaccine is stable, non-allergen, antigen; it also has a high-quality 3D structure, and numerous linear and conformational B cell epitopes, whereby this vaccine may stimulate efficient humoral immunity.

Conclusion: Center on the collected results, the designed vaccine potentially can induce cellular and humoral immune responses in HCC cases; nonetheless, the efficiency of vaccine must be approved within in vitro and in vivo immunological analyzes.

中文翻译：

---

新型抗肝细胞多表位肽疫苗的计算机设计

背景：肝细胞癌（HCC）是世界上流行的癌症。迄今为止，还没有药物可以完全治疗HCC。

目的：迫切需要寻找一种创新的肝癌治疗方法。最近，多表位疫苗已被引入作为针对HCC的有效免疫疗法。

方法：在这项研究中，几种免疫信息学方法被用于创建针对HCC的原始多表位疫苗，该疫苗由CD8 +溶细胞性T淋巴细胞（CTL）表位组成，这些表位选自α-甲胎蛋白（AFP），glypican-3（GPC3），aspartyl-β -羟化酶（ASPH）；来自破伤风毒素片段C（TTFC）的CD4 +辅助T淋巴细胞（HTL）表位，最后使用HSP70407-426的两个串联重复序列刺激强烈的先天性和适应性免疫反应。所有提到的部分都通过相关的链接器连接在一起。

结果与讨论：根据理化，结构和免疫学结果，设计的疫苗是稳定的，非过敏原，抗原。它也具有高质量的3D结构以及众多的线性和构象B细胞表位，因此该疫苗可刺激有效的体液免疫。

结论：从收集的结果来看，设计的疫苗可能在肝癌患者中诱导细胞和体液免疫反应。但是，疫苗的有效性必须在体外和体内免疫学分析中得到认可。